Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Erythro-Hydrobupropion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 2/20 | 0.63 |
| ▸ | SLC6A2 known ✓ | P23975 | 4/20 | 0.51 |
| ▸ | SLC6A3 known ✓ | Q01959 | 3/20 | 0.49 |
| ▸ | CHRNA1 known ✓ | P02708 | 1/20 | 0.49 |
| ▸ | CHRNG known ✓ | P07510 | 1/20 | 0.49 |
| ▸ | CHRNB1 known ✓ | P11230 | 1/20 | 0.49 |
| ▸ | CHRNB4 known ✓ | P30926 | 1/20 | 0.49 |
| ▸ | CHRNA3 known ✓ | P32297 | 1/20 | 0.49 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.49 |
| ▸ | CHRNA7 known ✓ | P36544 | 1/20 | 0.49 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.49 |
| ▸ | CHRND known ✓ | Q07001 | 1/20 | 0.49 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.49 |
| ▸ | SCN1A known ✓ | P35498 | 1/20 | 0.40 |
| ▸ | SCN2A known ✓ | Q99250 | 1/20 | 0.40 |
| ▸ | SCN3A known ✓ | Q9NY46 | 1/20 | 0.40 |
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.40 |
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 0.40 |
| ▸ | ADRB3 known ✓ | P13945 | 1/20 | 0.40 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Erythro-Hydrobupropion SCHEMBL6432011 | 1.00 | SLC6A4 (0.63) | SLC6A4SLC6A2ALDH1A1BLMSMN1; SMN2 | |
| Erythro-Hydrobupropion SCHEMBL6429469 | 1.00 | SLC6A4 (0.63) | SLC6A4SLC6A2ALDH1A1BLMSMN1; SMN2 | |
| Erythro-Hydrobupropion SCHEMBL6431996 | 1.00 | SLC6A4 (0.63) | SLC6A4SLC6A2ALDH1A1BLMSMN1; SMN2 | |
| Erythro-Hydrobupropion SCHEMBL6429264 | 1.00 | SLC6A4 (0.63) | SLC6A4SLC6A2ALDH1A1BLMSMN1; SMN2 | |
| Erythro-Hydrobupropion SCHEMBL29465707 | 1.00 | SLC6A4 (0.63) | SLC6A4SLC6A2ALDH1A1BLMSMN1; SMN2 | |
| Erythro-Hydrobupropion SCHEMBL6429272 | 1.00 | SLC6A4 (0.63) | SLC6A4SLC6A2ALDH1A1BLMSMN1; SMN2 | |
| Erythro-Hydrobupropion SCHEMBL6429472 | 1.00 | SLC6A4 (0.63) | SLC6A4SLC6A2ALDH1A1BLMSMN1; SMN2 | |
| Erythro-Hydrobupropion SCHEMBL3320155 | 0.98 | SLC6A4 (0.65) | SLC6A4SLC6A2ALDH1A1BLMSMN1; SMN2 | |
| Erythro-Hydrobupropion SCHEMBL1229064 | 0.98 | SLC6A4 (0.65) | SLC6A4SLC6A2ALDH1A1BLMSMN1; SMN2 | |
| Erythro-Hydrobupropion SCHEMBL1226819 | 0.98 | SLC6A4 (0.65) | SLC6A4SLC6A2ALDH1A1BLMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1602369-A2 | Bupropion Metabolites and Methods of their Synthesis and Use | Sepracor, Inc. (US) | 2005-12-07 | — | — | EP | claimed |
| US-20020052341-A1 | Bupropion metabolites and methods of their synthesis and use | SEPRACOR INC. | 2002-05-02 | — | — | US | claimed |
| US-20120269767-A1 | Treatment of Neurodegenerative Diseases | BIOCOPEA LIMITED (GB) | 2012-10-25 | — | — | US | disclosed |
| US-8188152-B2 | 2-aminoalcohols for the treatment of neurodegenerative diseases | BIOCOPEA LIMITED (GB) | 2012-05-29 | — | — | US | disclosed |
| US-20090192229-A1 | 2-Aminoalcohols for the Treatment of Neurodegenerative Diseases | BIOCOPEA LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
| EP-1928443-A1 | 2-AMINOALCOHOLS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Sosei R&D Ltd. (GB) | 2008-06-11 | — | — | EP | disclosed |
| WO-2007034200-A1 | 2-AMINOALCOHOLS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SOSEI R & D LTD. (GB) | 2007-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052341-A1 | Bupropion metabolites and methods of their synthesis and use | MAOB, MAOA, HTR5A | SLC6A4 5/4885SLC6A2 6/4885SLC6A3 10/4885 |
| US-20120269767-A1 | Treatment of Neurodegenerative Diseases | SNCA, NLN, CLN6 | SLC6A4 127/4885SLC6A2 44/4885SLC6A3 48/4885 |
| US-20090192229-A1 | 2-Aminoalcohols for the Treatment of Neurodegenerative Diseases | CHRNA9, CHRNA2, CHRNA3 | SLC6A4 934/4885SLC6A2 388/4885SLC6A3 458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.